News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
Market overviews
Direct comparison of products for laboratory and process: Use the comprehensive market overviews to compare products according to your requirements and obtain further information from suppliers.
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
09-Jul-2010 - Crucell N.V. announced that Crucell and sanofi pasteur reached an agreement on a series of transactions to restructure their long standing partnership. Crucell will waive its right to terminate an existing license agreement between Crucell Switzerland and sanofi pasteur's subsidiary Shantha ...
25-Jun-2010 - Crucell N.V. announced the start of a discovery program leading to the development and commercialization of a universal respiratory syncytial virus (RSV) vaccine. The RSV vaccine will be designed to prevent severe infections with the most common RSV strains in infants and the elderly. This ...
16-Mar-2010 - Crucell N.V. announced the nomination of Mr. William (Bill) Burns, Mr. James Shannon and Mr. George Siber to join its Supervisory Board. The Supervisory Board of Crucell has nominated Mr. Burns, Mr. Shannon and Mr. Siber as new members of the Board, to be presented to Crucell's shareholders at ...
23-Oct-2009 - Crucell N.V. announced that preliminary results of the Phase I study of its HIV vaccine were presented at La Conférence AIDS Vaccine 2009 in Paris, France. The presentation was given by Dr Dan H. Barouch, MD, PhD, Associate Professor of Medicine, Division of Vaccine Research, Department of ...
22-Oct-2009 - Crucell N.V. announced that detailed results of the Phase II Philippines study of its rabies monoclonal antibody combination (CL 184) were presented at the XX Rabies in the Americas (RITA) Conference in Quebec, Canada. The presentation was given by Dr Beatriz P. Quiambao (MD), Chief Clinical ...
01-Oct-2009 - Crucell N.V. announced the launch of its own dedicated marketing and sales organization in the United Kingdom by acquiring an experienced team, to further strengthen its vaccine sales position in one of the largest vaccine markets in Europe. Crucell's UK team will market and sell Crucell's ...
30-Sep-2009 - Johnson & Johnson and Crucell N.V. announced that Johnson & Johnson, through its subsidiary Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Crucell have entered into a strategic collaboration focusing on the discovery, development and commercialization of monoclonal antibodies and vaccines for ...
30-Jul-2009 - The US-based PATH Malaria Vaccine Initiative (MVI), the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP), and Crucell N.V. announced a collaboration to accelerate development of a promising type of malaria vaccine. Through funding from the ...
25-Jun-2009 - Crucell N.V. announced the results of a second phase II clinical study of its investigational rabies monoclonal antibody combination, which started in May 2008 in the Philippines. Crucell has a collaboration and commercialization agreement with sanofi pasteur, the vaccines division of ...
03-Mar-2009 - Crucell N.V. announced that the journal Science published a study showing why Crucell's novel anti-influenza antibody is so effective against such a broad range of influenza virus subtypes. These characteristics make the Crucell antibody CR6261 a potentially revolutionary therapy against seasonal ...
© 1997-2024 LUMITOS AG, All rights reserved